[October 27, 2016]

Global Melanocortin Receptor 4 (MC4R) Pipeline Review, H2 2016 Featuring AstraZeneca, Mallinckrodt, Obexia, Palatin Technologies, Pfizer & Retrophin - Research and Markets

Research and Markets has announced the addition of the "Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016" report to their offering.

Melanocortin Receptor 4 (MC4R) pipeline Target (News - Alert) constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 7 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also revies key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

1. Introduction
2. Melanocortin Receptor 4 Overview
3. Therapeutics Development
4. Pipeline Products for Melanocortin Receptor 4 - Overview
5. Pipeline Products for Melanocortin Receptor 4 - Comparative Analysis
6. Melanocortin Receptor 4 - Therapeutics under Development by Companies
7. Melanocortin Receptor 4 - Therapeutics under Investigation by Universities/Institutes
8. Melanocortin Receptor 4 Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Melanocortin Receptor 4 - Products under Development by Companies
13. Melanocortin Receptor 4 - Products under Investigation by Universities/Institutes
14. Melanocortin Receptor 4 - Companies Involved in Therapeutics Development

• AstraZeneca Plc
• Mallinckrodt Plc
• Obexia AG
• Palatin Technologies, Inc.
• Pfizer Inc.
• Retrophin Inc.

For more information about this report visit http://www.researchandmarkets.com/research/72xh9r/melanocortin

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006460/en/

[ Back To TMCnet.com's Homepage ]